Schedule 13G ownership disclosure

Janux Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 47103J105

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Paradigm BioCapital Advisors LP

    Shares: 3,515,986.00 · Class: 6.0%

  • Paradigm BioCapital Advisors GP LLC

    Shares: 3,515,986.00 · Class: 6.0%

  • Senai Asefaw, M.D.

    Shares: 3,515,986.00 · Class: 6.0%

  • Paradigm BioCapital International Fund Ltd.

    Shares: 3,030,509.00 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-014233
Form type
SCHEDULE 13G/A
Filer
Janux Therapeutics, Inc.
CIK
CIK 1817713
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub